Evidence map›Paper›PMID 35763933›Full record

ArticleComputers in biology and medicine2022

Structural basis of Omicron immune evasion: A comparative computational study.

Darshan Contractor, Christoph Globisch, Shiv Swaroop, Alok Jain

Open access · greenAbstract read
In one paragraph

Article in Computers in biology and medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Darshan ContractorDepartment of Bioengineering and Biotechnology, Birla Institute of Technology (BIT), Mesra, Ranchi, 835215, Jharkhand, India; Department of Biotechnology, Sun Pharmaceutical Industries Ltd., Tandalja, Vadodara, 390012, Gujarat, India.
Christoph GlobischDepartment of Chemistry, University of Konstanz, Germany.
Shiv SwaroopDepartment of Biochemistry, Central University of Rajasthan, NH-8, Bandar Sindri, Ajmer, 305817, Rajasthan, India. Electronic address: shivswaroop@curaj.ac.in.
Alok JainDepartment of Bioengineering and Biotechnology, Birla Institute of Technology (BIT), Mesra, Ranchi, 835215, Jharkhand, India. Electronic address: alokjain@bitmesra.ac.in.
Birla Institute of Technology, Mesra · INCentral University of Rajasthan · INUniversity of Konstanz · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe vaccines used against SARS-CoV-2 by now have been able to develop some neutralising antibodies in the vaccinated population and their effectiveness has been challenged by the emergence of the new strains with numerous mutations in the spike protein of SARS-CoV-2. Since S protein is the major immunogenic protein of the virus which contains Receptor Binding Domain (RBD) that interacts with the human Angiotensin-Converting Enzyme 2 (ACE2) receptors, any mutations in this region should affect the neutralisation potential of the antibodies leading to the immune evasion. Several variants of concern of the virus have emerged so far, amongst which the most critical are Delta and recently reported Omicron. In this study, we have mapped and reported mutations on the modelled RBD and evaluated binding affinities of various human antibodies with it.

methodDocking and molecular dynamics simulation studies have been used to explore the effect of mutations on the structure of RBD and RBD-antibody interaction.

resultsThese analyses show that the mutations mostly at the interface of a nearby region lower the binding affinity of the antibody by ten to forty percent, with a downfall in the number of interactions formed as a whole. It implies the generation of immune escape variants.

conclusionsNotable mutations and their effect was characterised that explain the structural basis of antibody efficacy in Delta and a compromised neutralisation effect for the Omicron variant. Thus, our results pave the way for robust vaccine design that can be effective for many variants.

Indexed as

COVID-19Spike Glycoprotein, CoronavirusHumansImmune EvasionMutationSARS-CoV-2Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Compromised neutralisationMolecular dockingMolecular dynamics simulationsOmicronSARS-CoV-2 variants

Identifiers

PMID35763933
PMCPMC9212419
OpenAlexW4283160949

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.